Eupraxia Pharmac Financials
Eupraxia Pharmac (EPRX) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Eupraxia Pharmac does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Eupraxia Pharmac passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Eupraxia Pharmac reported a net loss of $38.6M while operations used $28.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Eupraxia Pharmac generated $0 in revenue in fiscal year 2025.
Eupraxia Pharmac reported -$38.6M in net income in fiscal year 2025. This represents a decrease of 51.3% from the prior year.
Eupraxia Pharmac earned -$1.03 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 35.5% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Eupraxia Pharmac held $80.6M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Eupraxia Pharmac's ROE was -47.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 29.3 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Eupraxia Pharmac invested $21.3M in research and development in fiscal year 2025. This represents an increase of 32.7% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
EPRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | N/A |
| R&D Expenses | $21.3M+32.7% | $16.1M-21.0% | $20.4M+49.4% | $13.6M |
| SG&A Expenses | $17.1M+56.6% | $10.9M+46.0% | $7.5M+87.7% | $4.0M |
| Interest Expense | $0-100.0% | $604K-48.4% | $1.2M+19.1% | $983K |
| Income Tax | $19K+958.3% | $2K-95.0% | $36K | $0 |
| Net Income | -$38.6M-51.3% | -$25.5M+9.6% | -$28.2M-52.6% | -$18.5M |
| EPS (Diluted) | -$1.03-35.5% | -$0.76+35.0% | -$1.17-21.9% | -$0.96 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Operating Income.
EPRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Total Assets | $86.2M+146.5% | $34.9M+72.4% | $20.3M+6.0% | $19.1M |
| Current Assets | $85.1M+147.1% | $34.4M+73.9% | $19.8M+6.5% | $18.6M |
| Cash & Equivalents | $80.6M+143.4% | $33.1M+71.1% | $19.3M+5.9% | $18.3M |
| Accounts Receivable | $716K+177.5% | $258K+67.9% | $154K | N/A |
| Total Liabilities | $5.7M+83.8% | $3.1M-84.0% | $19.4M+62.6% | $11.9M |
| Current Liabilities | $5.6M+81.4% | $3.1M-84.0% | $19.4M+533.5% | $3.1M |
| Total Equity | $82.0M+145.6% | $33.4M+1407.3% | $2.2M-71.5% | $7.8M |
| Retained Earnings | -$169.6M-29.4% | -$131.0M-24.2% | -$105.5M-36.5% | -$77.3M |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
EPRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Operating Cash Flow | -$28.6M+4.8% | -$30.0M-44.6% | -$20.7M-44.1% | -$14.4M |
| Investing Cash Flow | -$589K-683.6% | -$75K-2.4% | -$73K-100.7% | $9.8M |
| Financing Cash Flow | $76.1M+66.1% | $45.8M+117.2% | $21.1M+95.2% | $10.8M |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
EPRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Return on Equity | -47.0%+29.3pp | -76.3%+1197.0pp | -1273.4%-1035.9pp | -237.5% |
| Return on Assets | -44.8%+28.2pp | -73.0%+66.3pp | -139.3%-42.6pp | -96.7% |
| Current Ratio | 15.12+4.0x | 11.10+10.1x | 1.02-5.1x | 6.08 |
| Debt-to-Equity | 0.070.0x | 0.09-8.6x | 8.74+7.2x | 1.53 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Eupraxia Pharmac Ranks
Frequently Asked Questions
What is Eupraxia Pharmac's annual revenue?
Eupraxia Pharmac (EPRX) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Eupraxia Pharmac profitable?
No, Eupraxia Pharmac (EPRX) reported a net income of -$38.6M in fiscal year 2025.
What is Eupraxia Pharmac's return on equity (ROE)?
Eupraxia Pharmac (EPRX) has a return on equity of -47.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Eupraxia Pharmac's operating cash flow?
Eupraxia Pharmac (EPRX) recorded an outflow of $28.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Eupraxia Pharmac's total assets?
Eupraxia Pharmac (EPRX) had $86.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Eupraxia Pharmac spend on research and development?
Eupraxia Pharmac (EPRX) invested $21.3M in research and development during fiscal year 2025.
What is Eupraxia Pharmac's current ratio?
Eupraxia Pharmac (EPRX) had a current ratio of 15.12 as of fiscal year 2025, which is generally considered healthy.
What is Eupraxia Pharmac's debt-to-equity ratio?
Eupraxia Pharmac (EPRX) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Eupraxia Pharmac's return on assets (ROA)?
Eupraxia Pharmac (EPRX) had a return on assets of -44.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Eupraxia Pharmac's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Eupraxia Pharmac (EPRX) held $80.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $28.6M over that year. Dividing the one by the other, the reported balance equals about 34 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Eupraxia Pharmac's Piotroski F-Score?
Eupraxia Pharmac (EPRX) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Eupraxia Pharmac's earnings high quality?
Eupraxia Pharmac (EPRX) reported a net loss of $38.6M while operations used $28.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.